RA Capital Management’s Akari Therapeutics AKTX Stock Holding History

RA Capital Management’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-127	Closed	-$714K	–	26
2016 Q4	$714K	Sell	127 -16	-11%	-$103K	0.1%	26
2016 Q3	$970K	Sell	143 -150	-51%	-$1.17M	0.1%	30
2016 Q2	$3.16M	Sell	293 -29	-9%	-$374K	0.44%	27
2016 Q1	$2.6M	Sell	322 -8	-2%	-$82.9K	0.33%	37
2015 Q4	$3.83M	Hold	330	–	–	0.38%	33
2015 Q3	$6.33M	Buy	+330	New	+$3.9M	0.91%	32

Other funds holding AKTX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RA Capital Management's AKTX Position: Q1 2017 in Review

RA Capital Management sold out of Akari Therapeutics (AKTX) in Q1 2017, closing a stake of 127 shares — an estimated $714K sold.

RA Capital Management first reported a position in AKTX in Q3 2015 and held it in 6 quarters. The position peaked at $6.33M in Q3 2015. 11 funds tracked by Wall St. Rank hold AKTX as of Q1 2017.

RA Capital Management reported no remaining Akari Therapeutics position as of Q1 2017 after selling out during the quarter.
RA Capital Management sold 127 Akari Therapeutics shares in Q1 2017, an estimated $714K.
RA Capital Management first reported a position in Akari Therapeutics in Q3 2015 and held it in 6 quarters.
RA Capital Management's Akari Therapeutics position peaked at $6.33M in Q3 2015.
11 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2017.

Based on RA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.